Annual FCF
-$16.44 M
+$10.53 M+39.05%
December 31, 2023
Summary
- As of February 21, 2025, MRKR annual free cash flow is -$16.44 million, with the most recent change of +$10.53 million (+39.05%) on December 31, 2023.
- During the last 3 years, MRKR annual FCF has risen by +$12.85 million (+43.87%).
- MRKR annual FCF is now -685100.00% below its all-time high of $2400.00, reached on December 31, 2001.
Performance
MRKR Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
$1.20 M
+$4.77 M+133.57%
September 30, 2024
Summary
- As of February 21, 2025, MRKR quarterly free cash flow is $1.20 million, with the most recent change of +$4.77 million (+133.57%) on September 30, 2024.
- Over the past year, MRKR quarterly FCF has increased by +$4.77 million (+133.57%).
- MRKR quarterly FCF is now -27.75% below its all-time high of $1.66 million, reached on June 30, 2022.
Performance
MRKR Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$8.57 M
+$2.33 M+21.33%
September 30, 2024
Summary
- As of February 21, 2025, MRKR TTM free cash flow is -$8.57 million, with the most recent change of +$2.33 million (+21.33%) on September 30, 2024.
- Over the past year, MRKR TTM FCF has increased by +$2.33 million (+21.33%).
- MRKR TTM FCF is now -357383.33% below its all-time high of $2400.00, reached on December 31, 2001.
Performance
MRKR TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
MRKR Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +39.0% | +133.6% | +21.3% |
| 3 y3 years | +43.9% | +133.6% | +21.3% |
| 5 y5 years | -12.4% | +114.7% | +62.1% |
MRKR Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +45.9% | -27.8% | +108.2% | at high | +75.9% |
| 5 y | 5-year | at high | +45.9% | -27.8% | +108.2% | at high | +75.9% |
| alltime | all time | <-9999.0% | +45.9% | -27.8% | +108.2% | <-9999.0% | +75.9% |
Marker Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $1.20 M(-133.6%) | -$8.57 M(-21.3%) |
| Jun 2024 | - | -$3.57 M(-7.0%) | -$10.90 M(-24.2%) |
| Mar 2024 | - | -$3.84 M(+62.1%) | -$14.39 M(-12.5%) |
| Dec 2023 | -$16.44 M(-39.0%) | -$2.37 M(+110.0%) | -$16.44 M(-19.3%) |
| Sep 2023 | - | -$1.13 M(-84.0%) | -$20.38 M(-24.2%) |
| Jun 2023 | - | -$7.06 M(+19.8%) | -$26.90 M(+47.9%) |
| Mar 2023 | - | -$5.89 M(-6.6%) | -$18.18 M(-32.6%) |
| Dec 2022 | -$26.97 M(-11.3%) | -$6.31 M(-17.5%) | -$26.97 M(+4.2%) |
| Sep 2022 | - | -$7.65 M(-561.3%) | -$25.87 M(-3.3%) |
| Jun 2022 | - | $1.66 M(-111.3%) | -$26.74 M(-24.8%) |
| Mar 2022 | - | -$14.68 M(+181.8%) | -$35.59 M(+17.0%) |
| Dec 2021 | -$30.41 M(+3.8%) | -$5.21 M(-38.8%) | -$30.41 M(-12.6%) |
| Sep 2021 | - | -$8.52 M(+18.5%) | -$34.81 M(+3.5%) |
| Jun 2021 | - | -$7.19 M(-24.4%) | -$33.64 M(-2.7%) |
| Mar 2021 | - | -$9.50 M(-1.1%) | -$34.59 M(+18.1%) |
| Dec 2020 | -$29.29 M(+57.0%) | -$9.60 M(+30.6%) | -$29.29 M(+20.7%) |
| Sep 2020 | - | -$7.35 M(-9.6%) | -$24.26 M(+7.2%) |
| Jun 2020 | - | -$8.13 M(+93.6%) | -$22.62 M(+20.6%) |
| Mar 2020 | - | -$4.20 M(-8.2%) | -$18.75 M(+0.5%) |
| Dec 2019 | -$18.66 M(+27.6%) | -$4.57 M(-20.0%) | -$18.66 M(-7.8%) |
| Sep 2019 | - | -$5.72 M(+34.2%) | -$20.25 M(+11.9%) |
| Jun 2019 | - | -$4.26 M(+3.9%) | -$18.10 M(+11.5%) |
| Mar 2019 | - | -$4.10 M(-33.4%) | -$16.24 M(+12.1%) |
| Dec 2018 | -$14.63 M(+73.3%) | -$6.16 M(+72.5%) | -$14.48 M(+34.1%) |
| Sep 2018 | - | -$3.57 M(+48.9%) | -$10.80 M(+16.7%) |
| Jun 2018 | - | -$2.40 M(+2.3%) | -$9.25 M(+4.4%) |
| Mar 2018 | - | -$2.35 M(-5.3%) | -$8.86 M(+5.0%) |
| Dec 2017 | -$8.44 M(+29.6%) | -$2.48 M(+22.4%) | -$8.44 M(+9.4%) |
| Sep 2017 | - | -$2.03 M(+0.7%) | -$7.71 M(+0.7%) |
| Jun 2017 | - | -$2.01 M(+4.6%) | -$7.66 M(+0.8%) |
| Mar 2017 | - | -$1.92 M(+9.7%) | -$7.60 M(+16.8%) |
| Dec 2016 | -$6.51 M(+49.9%) | -$1.75 M(-11.1%) | -$6.51 M(+16.1%) |
| Sep 2016 | - | -$1.97 M(+0.9%) | -$5.61 M(+5.8%) |
| Jun 2016 | - | -$1.95 M(+135.5%) | -$5.30 M(+27.4%) |
| Mar 2016 | - | -$829.80 K(-2.5%) | -$4.16 M(-4.3%) |
| Dec 2015 | -$4.34 M(+98.6%) | -$851.00 K(-48.9%) | -$4.34 M(+4.4%) |
| Sep 2015 | - | -$1.66 M(+104.7%) | -$4.16 M(+22.3%) |
| Jun 2015 | - | -$813.20 K(-19.8%) | -$3.40 M(+20.3%) |
| Mar 2015 | - | -$1.01 M(+51.6%) | -$2.83 M(+29.3%) |
| Dec 2014 | -$2.19 M(+214.9%) | -$669.20 K(-26.2%) | -$2.19 M(+50.0%) |
| Sep 2014 | - | -$906.50 K(+280.1%) | -$1.46 M(+112.4%) |
| Jun 2014 | - | -$238.50 K(-36.1%) | -$686.40 K(+12.0%) |
| Mar 2014 | - | -$373.00 K(-721.7%) | -$613.10 K(-11.7%) |
| Dec 2013 | -$694.60 K(-56.3%) | $60.00 K(-144.5%) | -$694.60 K(-44.3%) |
| Sep 2013 | - | -$134.90 K(-18.3%) | -$1.25 M(-9.9%) |
| Jun 2013 | - | -$165.20 K(-63.7%) | -$1.38 M(-19.1%) |
| Mar 2013 | - | -$454.50 K(-7.7%) | -$1.71 M(+7.7%) |
| Dec 2012 | -$1.59 M | -$492.60 K(+80.9%) | -$1.59 M(+3.9%) |
| Sep 2012 | - | -$272.30 K(-44.6%) | -$1.53 M(+9.3%) |
| Jun 2012 | - | -$491.30 K(+47.8%) | -$1.40 M(+13.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$332.40 K(-23.3%) | -$1.24 M(-5.5%) |
| Dec 2011 | -$1.31 M(+41.6%) | -$433.10 K(+205.9%) | -$1.31 M(+43.9%) |
| Sep 2011 | - | -$141.60 K(-57.2%) | -$910.00 K(-11.1%) |
| Jun 2011 | - | -$330.70 K(-18.2%) | -$1.02 M(-9.0%) |
| Mar 2011 | - | -$404.40 K(+1114.4%) | -$1.12 M(+21.5%) |
| Dec 2010 | -$925.00 K(-17.5%) | -$33.30 K(-86.9%) | -$925.00 K(-30.1%) |
| Sep 2010 | - | -$254.80 K(-41.0%) | -$1.32 M(-9.2%) |
| Jun 2010 | - | -$431.50 K(+110.1%) | -$1.46 M(+26.1%) |
| Mar 2010 | - | -$205.40 K(-52.4%) | -$1.16 M(+3.1%) |
| Dec 2009 | -$1.12 M(+57.0%) | -$431.80 K(+10.8%) | -$1.12 M(+33.7%) |
| Sep 2009 | - | -$389.60 K(+201.1%) | -$838.70 K(+49.6%) |
| Jun 2009 | - | -$129.40 K(-24.2%) | -$560.70 K(-14.7%) |
| Mar 2009 | - | -$170.80 K(+14.7%) | -$657.20 K(-8.0%) |
| Dec 2008 | -$714.40 K(-43.8%) | -$148.90 K(+33.4%) | -$714.40 K(-41.4%) |
| Sep 2008 | - | -$111.60 K(-50.6%) | -$1.22 M(-6.7%) |
| Jun 2008 | - | -$225.90 K(-0.9%) | -$1.31 M(+6.0%) |
| Mar 2008 | - | -$228.00 K(-65.1%) | -$1.23 M(-3.0%) |
| Dec 2007 | -$1.27 M(-10.9%) | -$654.10 K(+227.9%) | -$1.27 M(+8.4%) |
| Sep 2007 | - | -$199.50 K(+31.7%) | -$1.17 M(+11.8%) |
| Jun 2007 | - | -$151.50 K(-43.1%) | -$1.05 M(-23.2%) |
| Mar 2007 | - | -$266.20 K(-52.1%) | -$1.37 M(-4.3%) |
| Dec 2006 | -$1.43 M(+22.4%) | -$556.10 K(+638.5%) | -$1.43 M(+53.3%) |
| Sep 2006 | - | -$75.30 K(-83.9%) | -$931.10 K(-6.1%) |
| Jun 2006 | - | -$468.10 K(+42.7%) | -$991.30 K(-13.2%) |
| Mar 2006 | - | -$328.10 K(+450.5%) | -$1.14 M(-2.1%) |
| Dec 2005 | -$1.17 M(-9.5%) | -$59.60 K(-56.0%) | -$1.17 M(-12.8%) |
| Sep 2005 | - | -$135.50 K(-78.1%) | -$1.34 M(-1.6%) |
| Jun 2005 | - | -$619.40 K(+75.9%) | -$1.36 M(+27.7%) |
| Mar 2005 | - | -$352.10 K(+52.8%) | -$1.06 M(-17.5%) |
| Dec 2004 | -$1.29 M(-50.3%) | -$230.50 K(+46.8%) | -$1.29 M(-29.4%) |
| Sep 2004 | - | -$157.00 K(-51.6%) | -$1.82 M(-15.1%) |
| Jun 2004 | - | -$324.40 K(-43.8%) | -$2.15 M(-10.3%) |
| Mar 2004 | - | -$577.10 K(-24.7%) | -$2.40 M(-7.5%) |
| Dec 2003 | -$2.59 M(+83.6%) | -$766.50 K(+58.9%) | -$2.59 M(+8.9%) |
| Sep 2003 | - | -$482.50 K(-15.7%) | -$2.38 M(+2.2%) |
| Jun 2003 | - | -$572.40 K(-25.9%) | -$2.33 M(+16.6%) |
| Mar 2003 | - | -$772.20 K(+39.3%) | -$2.00 M(+42.1%) |
| Dec 2002 | -$1.41 M(<-9900.0%) | -$554.40 K(+28.4%) | -$1.41 M(+215.9%) |
| Sep 2002 | - | -$431.90 K(+79.2%) | -$445.40 K(+5.8%) |
| Jun 2002 | - | -$241.00 K(+34.3%) | -$420.90 K(+307.8%) |
| Mar 2002 | - | -$179.50 K(-144.1%) | -$103.20 K(-4400.0%) |
| Dec 2001 | $2400.00(-100.3%) | $407.00 K(-199.9%) | $2400.00(-100.6%) |
| Sep 2001 | - | -$407.40 K(-631.2%) | -$426.10 K(+31.7%) |
| Jun 2001 | - | $76.70 K(-203.8%) | -$323.60 K(-52.8%) |
| Mar 2001 | - | -$73.90 K(+243.7%) | -$685.20 K(-22.4%) |
| Dec 2000 | -$882.60 K(+1.5%) | -$21.50 K(-92.9%) | -$882.50 K(+2.5%) |
| Sep 2000 | - | -$304.90 K(+7.0%) | -$861.00 K(+54.8%) |
| Jun 2000 | - | -$284.90 K(+5.1%) | -$556.10 K(+105.1%) |
| Mar 2000 | - | -$271.20 K | -$271.20 K |
| Dec 1999 | -$869.20 K | - | - |
FAQ
- What is Marker Therapeutics annual free cash flow?
- What is the all time high annual FCF for Marker Therapeutics?
- What is Marker Therapeutics annual FCF year-on-year change?
- What is Marker Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Marker Therapeutics?
- What is Marker Therapeutics quarterly FCF year-on-year change?
- What is Marker Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Marker Therapeutics?
- What is Marker Therapeutics TTM FCF year-on-year change?
What is Marker Therapeutics annual free cash flow?
The current annual FCF of MRKR is -$16.44 M
What is the all time high annual FCF for Marker Therapeutics?
Marker Therapeutics all-time high annual free cash flow is $2400.00
What is Marker Therapeutics annual FCF year-on-year change?
Over the past year, MRKR annual free cash flow has changed by +$10.53 M (+39.05%)
What is Marker Therapeutics quarterly free cash flow?
The current quarterly FCF of MRKR is $1.20 M
What is the all time high quarterly FCF for Marker Therapeutics?
Marker Therapeutics all-time high quarterly free cash flow is $1.66 M
What is Marker Therapeutics quarterly FCF year-on-year change?
Over the past year, MRKR quarterly free cash flow has changed by +$4.77 M (+133.57%)
What is Marker Therapeutics TTM free cash flow?
The current TTM FCF of MRKR is -$8.57 M
What is the all time high TTM FCF for Marker Therapeutics?
Marker Therapeutics all-time high TTM free cash flow is $2400.00
What is Marker Therapeutics TTM FCF year-on-year change?
Over the past year, MRKR TTM free cash flow has changed by +$2.33 M (+21.33%)